It’s the world’s largest research-focused patient organization for one of the most prevalent forms of muscular dystrophy. The FSHD Society is working toward a cure to end the pain endured by one ...

Please provide your email address to receive an email when new articles are posted on . Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No ...

Solve FSHD and Modalis Therapeutics Corp. have established a strategic collaboration to develop an innovative therapy for facioscapulohumeral muscular dystrophy (FSHD).

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that affects muscle function, often making everyday tasks — like smiling or lifting one’s arms — difficult. For individuals ...

- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root cause ...

New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is associated with meaningful improvements in muscle mass, strength, and mobility ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for ...

"Facioscapulohumeral Muscular Dystrophy Market"In the year 2021, the total prevalent cases of FSHD were 78,790 in the 7MM which are expected to grow during the study period, i.e., 2019–2032. The ...